





# Immunology

Antibodies for Immunology Research





[bioxcell.com](http://bioxcell.com)




# Antibodies for Immunology Research





Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
2C TCR	mouse	IF, FC	1B2	BE0069	BE0083
4-1BB (CD137)	mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BP0169	BP0089
4-1BB (CD137)	mouse	<i>in vivo</i> and <i>in vitro</i> 4-1BB stimulation	3H3	BP0239	BP0089
4-1BB (CD137)	mouse	<i>in vitro</i> 4-1BB blockade, FC	17B5	BE0296	BE0087
4-1BBL (CD137L)	mouse	<i>in vivo</i> 4-1BBL blockade	TKS-1	BE0110	BE0089
B220	mouse	<i>in vivo</i> B cell depletion, <i>in vitro</i> B cell negative selection	RA3.3A1/6.1	BE0067	BE0094
B7-1 (CD80)	mouse	<i>in vivo</i> B7-1 blockade, Affinity chromatography	1G10	BE0134	BE0089
BTLA (CD272)	mouse	<i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade	6A6	BE0132	BE0091
BTLA (CD272)	mouse	<i>in vivo</i> and <i>in vitro</i> stimulation of BTLA, FC	PK18.6	BE0153	BE0088
BTLA (CD272)	mouse	<i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC	PJ196	BE0196	BE0083
BTLA (CD272)	mouse	<i>in vivo</i> BTLA+ B cell and CD4 T cell depletion, FC	6F7	BE0304	BE0083
c-Kit (CD117)	mouse	FC, IF, IHC	2B8	BE0280	BE0090
c-Kit (CD117)	mouse	<i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit <sup>+</sup> cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC	ACK2	BE0293	BE0090
CCL2 (MCP-1)	mouse/human/rat	<i>in vivo</i> CCL2 neutralization, IHC-F	2H5	BE0185	BE0091
CCR3 (CD193)	mouse	<i>in vivo</i> eosinophil depletion	6S2-19-4	BE0316	BE0090
CD1a	human	<i>in vitro</i> CD1a blockade, FC	OKT-6	BE0211	BE0083
CD1d (CD1.1)	mouse	<i>in vivo</i> CD1d neutralization	19G11	BE0000	BE0088
CD1d (CD1.1)	mouse	<i>in vivo</i> CD1d blockade, iNKT cell neutralization, FC	20H2 (HB323)	BE0179	BE0088
CD3	human	<i>in vivo</i> T cell depletion in humanized mice, <i>in vitro</i> T cell stimulation/activation, ex vivo T cell inhibition for xenographs, FC	OKT-3	BE0001-2	BE0085
CD3	mouse	<i>in vitro</i> T cell stimulation/activation	17A2	BE0002	BE0090
CD3	human	<i>in vivo</i> T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC	UCHT1 (Leu-4) (T3)	BE0231	BE0083
CD3ε	mouse	<i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC	145-2C11	BP0001-1	BP0091
CD3ε	mouse	<i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF	KT3	BE0261	BE0089
CD3ε F(ab) <sub>2</sub> fragment	mouse	<i>in vivo</i> T cell depletion	145-2C11 f(ab) <sub>2</sub> Fragments	BE0001-1FAB	BE0091-FAB
CD4	mouse	<i>in vivo</i> CD4 <sup>+</sup> T cell depletion, FC	GK1.5	BP0003-1	BP0090
CD4	human	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4 <sup>+</sup> T cell depletion in humanized mice, FC, IP	OKT-4	BE0003-2	BE0086
CD4	mouse	<i>in vivo</i> blockade of CD4 <sup>+</sup> T-cell responses, WB	YTS 177	BE0003-3	BE0089
CD4	mouse	<i>in vivo</i> CD4 <sup>+</sup> T cell depletion	YTS 191	BE0119	BE0090
CD4	human	<i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4 <sup>+</sup> T cell activation, IF, IHC-F, FC	RPA-T4	BE0288	BE0083
CD4	rat	<i>in vivo</i> CD4 <sup>+</sup> T cell depletion, FC	OX-38	BE0308	BE0085
CD8 (Lyt 2.1)	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion, FC	116-13.1 (HB129)	BE0118	BE0085
CD8α	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion, IF, FC	53-6.7	BP0004-1	BP0089
CD8α	human	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion in humanized mice	OKT-8	BE0004-2	BE0085
CD8α	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion	2.43	BP0061	BP0090
CD8α	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion	YTS 169.4	BE0117	BP0090
CD8β (Lyt 3.2)	mouse	<i>in vivo</i> CD8 <sup>+</sup> T cell depletion, <i>in vitro</i> CD8 blockade, IF	53-5.8	BE0223	BE0088
CD11b	mouse/human	<i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC	M1/70	BE0007	BE0090
CD16/CD32	mouse	<i>in vitro</i> and <i>in vivo</i> Fc receptor blocking	2.4G2	BE0307	BE0090
CD19	mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	BE0089
CD19	human	Functional assays, Chimeric antigen receptor construction, FC, IF	4G7	BE0281	BE0083
CD20	mouse	<i>in vivo</i> B cell depletion, WB	MB20-11	BP0356	BP0366
CD22	mouse	<i>in vivo</i> B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), FC, IP	Cy34.1	BE0011	BE0083
CD24	mouse	<i>in vivo</i> administration, IHC-F, IHC-P, IF, FC	M1/69	BE0360	BE0090
CD25 (IL-2Rα)	mouse	<i>in vivo</i> regulatory T cell depletion, FC	PC-61.5.3	BP0012	BP0088
CD25 (IL-2Rα)	human	IP, IF	7G7B6	BE0014	BE0085
CD27	mouse	<i>in vivo</i> CD27 stimulation, <i>in vitro</i> CD27 stimulation, IP, FC	RM27-3E5	BE0348	BE0089
CD28	mouse	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade	37.51	BE0015-1	BE0087
CD28	mouse	<i>in vitro</i> T cell stimulation/activation	PV-1	BE0015-5	BE0091
CD28	mouse	<i>in vivo</i> and <i>in vitro</i> T cell stimulation/activation	D665	BE0328	BE0083
CD32 (FcγRIIA)	human	<i>in vivo</i> FcγRIIA blockade in humanized mice, <i>in vitro</i> FcγRIIA blockade, ELISA, FC	IV.3	BE0224	BE0086
CD38	mouse	<i>in vivo</i> and <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF	NIMR5	BE0317	BE0089
CD40	mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5/FGK45	BE0016-2	BP0016-2



Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CD40	human	<i>in vitro</i> B cell stimulation, <i>in vitro</i> macrophage stimulation, Functional assays, FC	G28.5	BE0189	BE0083
CD40L (CD154)	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling	MR-1	BE0017-1	BP0091
CD40L (CD154)	human/monkey	<i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling, IP, FC	5C8	BE0292	BE0085
CD45RB	mouse	<i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion	MB23G2 (HB220)	BE0019	BE0089
CD45.2	mouse	FC, IHC-F, <i>in vitro</i> CD45.2 blockade, <i>in vivo</i> CD45.2 blockade	104.2	BE0300	BE0085
CD47	human	<i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, <i>in vitro</i> CD47 neutralization, FC	B6H12	BE0019-1	BE0083
CD47	human/mouse/rat	<i>in vivo</i> and <i>in vitro</i> CD47 blockade, IF	MIAP410	BE0283	BP0083
CD47 (IAP)	mouse	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF	MIAP301	BE0270	BE0089
CD48	mouse	<i>in vivo</i> and <i>in vitro</i> CD48 blockade	HM48-1	BE0147	BE0091
CD54 (ICAM-1)	mouse	<i>in vivo</i> ICAM-1 neutralization	YNI/1.7.4	BE0020-1	BE0090
CD69	mouse	<i>in vivo</i> down-regulation of CD69 expression, Functional assays	CD69.2.2	BE0330	BE0083
CD70	mouse	<i>in vivo</i> and <i>in vitro</i> CD70 blockade, FC	FR70	BE0022	BE0090
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3/TIB-219	BP0175	BP0089
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BP0329	BP0089
CD71 (TfR1)	rat/mouse	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	BE0085
CD73	mouse	<i>in vivo</i> CD73 blockade	TY/23	BE0209	BE0089
CD80 (B7-1)	mouse	<i>in vivo</i> CD80 blockade, FC	16-10A1	BE0024	BE0091
CD86 (B7-2)	mouse	<i>in vivo</i> CD86 blockade, FC	GL-1	BE0025	BE0089
CD96	mouse	<i>in vivo</i> and <i>in vitro</i> CD96 blocking, FC	3.3	BE0337	BE0088
CD103	mouse	<i>in vivo</i> CD103 neutralization, IF, FC	M290	BE0026	BE0089
CD106 (VCAM-1)	mouse	<i>in vivo</i> VCAM-1 neutralization, IF	M/K-2.7	BE0027	BE0088
CD122 (IL-2Rβ)	mouse	<i>in vitro</i> NK cell negative selection, IP, FC	5H4	BE0272	BE0089
CD122 (IL-2Rβ)	mouse	<i>in vivo</i> NK cell depletion, <i>in vitro</i> IL-2R blockade, Functional assays, FC	TM-Beta 1	BE0298	BE0090
CD132 (common γ chain)	mouse	<i>in vivo</i> γc blockade, Functional assays, IP, FC	3E12	BE0271	BE0090
CD172a (SIRPα)	mouse	<i>in vivo</i> and <i>in vitro</i> SIRPα blocking, WB, IP, FC	P84	BE0322	BE0088
CD200 (OX2)	mouse	<i>in vivo</i> and <i>in vitro</i> CD200 blockade, IHC-F, IF, FC	OX-90	BE0299	BE0089
CD209b (SIGN-R1)	mouse	<i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC	22D1	BE0220	BE0091
CD276 (B7-H3)	mouse	<i>in vivo</i> B7-H3 blockade, FC	MJ18	BE0124	BE0088
CD314 (NKG2D)	mouse	<i>in vivo</i> and <i>in vitro</i> NKG2D blockade, FC	CX5	BE0334	BE0088
CD317 (BST2, PDCA-1)	mouse	<i>in vivo</i> pDC depletion, IF, FC	927	BE0311	BE0090
CLEC9A (CD370)	mouse	<i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC	7H11	BE0305	BE0088
CSF1	mouse	<i>in vitro</i> CSF1 neutralization	5A1	BE0204	BE0088
CSF1R (CD115)	mouse	<i>in vivo</i> macrophage depletion, <i>in vivo</i> monocyte depletion, <i>in vitro</i> CSF-R1 neutralization, FC	AFS98	BE0213	BP0089
CTLA-4 (CD152)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC	UC10-4F10-11	BE0032	BP0091
CTLA-4 (CD152)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization	9H10	BE0131	BP0087
CTLA-4 (CD152)	mouse	<i>in vivo</i> CTLA-4 neutralization	9D9	BE0164	BP0086
CTLA-4 (CD152)	human	<i>in vitro</i> CTLA-4 neutralization, FC	BN13	BE0190	BE0085
CXCL9 (MIG)	mouse	IF	MIG-2F5.5	BE0309	BE0091
CXCR3 (CD183)	mouse	<i>in vivo</i> CXCR3 neutralization, FC	CXCR3-173	BE0249	BE0091
Delta-like protein 4 (DLL4)	mouse	<i>in vivo</i> DLL4 neutralization	HMD4-2	BE0127	BE0091
DR5 (CD262)	mouse	<i>in vivo</i> induction TRAIL-mediated apoptosis, <i>in vitro</i> induction TRAIL-mediated apoptosis	MD5-1	BE0161	BE0091
F4/80	mouse	<i>in vivo</i> Monocyte/Macrophage depletion, Functional assays, IHC-P, IHC-F, FC	Cl:A3-1	BE0206	BE0090
FasL (CD178)	mouse	<i>in vivo</i> and <i>in vitro</i> FasL blockade, Functional assay, IHC-P, FC	MFL3	BE0319	BE0091
FGL-1	mouse	<i>in vivo</i> and <i>in vitro</i> FGL-1 blockade, FC, IHC-P	177R4	BE0332	BE0083
Galectin-9	mouse	<i>in vivo</i> and <i>in vitro</i> Galectin-9 blockade	RG9-1	BE0218	BE0090
GITR	mouse	<i>in vivo</i> GITR stimulation	DTA-1	BE0063	BP0090
GM-CSF	mouse	<i>in vivo</i> and <i>in vitro</i> GM-CSF neutralization, FC	MP1-22E9	BE0259	BE0089
ICOS	mouse	<i>in vivo</i> blocking of ICOS/ICOSL signaling, FC	7E.17G9	BE0059	BE0090
ICOSL (CD275)	mouse	<i>in vivo</i> ICOSL neutralization	HK5.3	BE0028	BE0089
IFNAR-1	mouse	<i>in vivo</i> and <i>in vitro</i> IFNAR-1 blockade	MAR1-5A3	BE0241	BP0083
IFNγ	mouse	<i>in vivo</i> and <i>in vitro</i> IFNγ neutralization	R4-6A2	BE0054	BE0088
IFNγ	mouse	<i>in vivo</i> and <i>in vitro</i> IFNγ neutralization, ELISPOT, FC	XMG1.2	BE0055	BP0088



Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
IFN $\gamma$	human	<i>in vitro</i> IFN $\gamma$ neutralization	B133.5	BE0235	BE0083
IFN $\gamma$	human	FC	B27	BE0245	BE0083
IFN $\gamma$	mouse	<i>in vivo</i> and <i>in vitro</i> IFN $\gamma$ neutralization	H22	BE0312	BE0091
IFN $\gamma$ R (CD119)	mouse	<i>in vivo</i> IFN $\gamma$ R neutralization	GR-20	BE0029	BE0089
IFN $\gamma$ R $\alpha$ (CD119)	mouse	WB, IP, FC	2E2	BE0287	BE0091
IL-1 R (CD121a)	mouse	<i>in vitro</i> IL-1 R blockade	JAMA-147	BE0256	BE0091
IL-1 $\alpha$	mouse	<i>in vivo</i> IL-1 $\alpha$ neutralization	ALF-161	BE0243	BE0091
IL-1 $\beta$	mouse/rat	<i>in vivo</i> and <i>in vitro</i> IL-1 $\beta$ neutralization, ELISA	B122	BE0246	BE0091
IL-2	mouse	<i>in vivo</i> and <i>in vitro</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, FC	JES6-5H4	BE0042	BE0090
IL-2	mouse	<i>in vivo</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2)	JES6-1A12	BE0043	BE0089
IL-2	mouse	<i>in vivo</i> IL-2 neutralization, <i>in vivo</i> IL-2 receptor stimulation (as a complex with IL-2)	S4B6-1	BE0043-1	BE0089
IL-3	mouse	<i>in vivo</i> and <i>in vitro</i> IL-3 neutralization, <i>in vivo</i> IL-3 receptor stimulation (as a complex with IL-3), ELISA, FC	MP2-8F8	BE0282	BE0088
IL-4	mouse	<i>in vitro</i> and <i>in vivo</i> IL-4 neutralization, <i>in vivo</i> IL-4 receptor stimulation (as a complex with IL-4), FC	11B11	BP0045	BP0088
IL-4	mouse	ELISA, ELISPOT, FC	BVD6-24G2	BE0199	BE0088
IL-4	human	<i>in vitro</i> IL-4 neutralization, FC	MP4-25D2	BE0240	BE0088
IL-5	mouse/human	<i>in vivo</i> IL-5 neutralization, <i>in vivo</i> eosinophil depletion	TRFK5	BE0198	BE0088
IL-6	mouse	<i>in vivo</i> IL-6 neutralization, <i>in vitro</i> IL-6 neutralization	MP5-20F3	BE0046	BE0088
IL-6R	mouse	<i>in vivo</i> blocking of IL-6/IL-6R signaling, <i>in vitro</i> blocking of IL-6R signaling	15A7	BE0047	BE0090
IL-7	mouse/human	<i>in vivo</i> IL-7 neutralization, <i>in vivo</i> IL-7 receptor stimulation (as a complex with IL-7)	M25	BE0048	BE0086
IL-7R $\alpha$ (CD127)	mouse	<i>in vivo</i> blocking of IL-7R $\alpha$ signaling, FC	A7R34	BE0065	BE0089
IL-9	mouse	<i>in vivo</i> IL-9 neutralization	9C1	BE0181	BE0085
IL-9	HUMAN	FC, ELISA	MH9A4	BE0327	BE0086
IL-10	mouse	<i>in vivo</i> IL-10 neutralization, <i>in vitro</i> IL-10 neutralization	JES5-2A5	BE0049	BE0088
IL-10R (CD210)	mouse	<i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC	1B1.3A	BP0050	BP0088
IL-12	mouse	<i>in vitro</i> IL-12 neutralization	R1-5D9	BE0052	BE0089
IL-12 p40	mouse	<i>in vivo</i> IL-12p40 neutralization, p40 affinity chromatography, IP, ELISA, FC, WB	C17.8	BP0051	BP0089
IL-12 p70	human	Functional assays, ELISA, FC	20C2	BE0234	BE0088
IL-12 p75	mouse	<i>in vivo</i> IL-12p75 neutralization, ELISA	R2-9A5	BE0233	BE0090
IL-15	mouse	<i>in vivo</i> and <i>in vitro</i> IL-15 neutralization	AIO.3	BE0315	BE0089
IL-17A	mouse	<i>in vivo</i> IL-17A neutralization	17F3	BP0173	BP0083
IL-17F	mouse	<i>in vivo</i> IL-17F neutralization	MM17F8F5.1A9	BE0303	BE0083
IL-18	mouse	<i>in vivo</i> IL-18 neutralization	YIGIF74-1G7	BE0237	BE0089
IL-21R	mouse	<i>in vivo</i> IL-21R blockade	4A9	BE0258	BE0089
IL-23 (p19)	mouse	<i>in vivo</i> IL-23/IL-23R neutralization; WB	G23-8	BE0313	BE0088
IL-27 p28	mouse	<i>in vivo</i> and <i>in vitro</i> IL-27 p28 neutralization, FC	MM27.7B1	BE0326	BE0085
Jagged2	mouse	<i>in vivo</i> Jagged 2 neutralization	HMJ2-1	BE0125	BE0091
Kappa Immunoglobulin Light Chain	rat	<i>in vivo</i> administration, FC	MAR 18.5	BE0122	BE0085
Kappa Immunoglobulin Light Chain	mouse	IF	187.1 (HB58)	BE0176	BE0088
KLRG-1	mouse/human	FC	2F1	BE0201	BE0087
LAG-3	mouse	<i>in vivo</i> and <i>in vitro</i> LAG-3 neutralization, FC	C9B7W	BP0174	BP0088
Ly6C	mouse	<i>in vivo</i> macrophage depletion (in combination with clodronate liposomes), FC	Monts 1	BE0203	BE0089
Ly6G	mouse	<i>in vivo</i> neutrophil depletion, <i>in vivo</i> MDSC depletion, IF, IHC-P, IHC-F, FC	1A8	BP0075-1	BP0089
Ly6G/Ly6C (Gr-1)	mouse	<i>in vivo</i> neutrophil depletion, IHC-P, IHC-F, IF, FC	NIMP-R14	BE0320	BE0090
Ly6G/Ly6C (Gr-1)	mouse	<i>in vivo</i> depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F	RB6-8C5	BP0075	BP0090
MDR-1 (CD243)	human/monkey	<i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P	UIC2	BE0340	BE0085
MHC Class I (H-2)	mouse	<i>ex vivo</i> blocking of MHC I-dependent interactions, IF, FC	M1/42.3.9.8	BE0077	BE0089
MHC Class I (H-2Kb)	mouse	<i>in vivo</i> administration, FC	AF6-88.5.5.3	BE0121	BE0085
MHC Class I (H-2Kb)	mouse	<i>in vivo</i> MHC II blockade, Functional assays, Purification of MHC peptide complexes, FC	Y-3	BE0172	BE0086
MHC Class I (H-2Kb) bound to SIINFEKL	mouse	<i>in vivo</i> blocking of Kb-SIINFEKL, Functional assays, FC	25-D1.16	BE0207	BE0083
MHC Class I (H-2Kd, H-2Dd)	mouse	<i>in vivo</i> activation of APCs	34-1-2S	BE0180	BE0085
MHC Class I (H-2Kd)	mouse	<i>in vivo</i> administration, Purification of MHC peptide complexes, FC	SF11.10 (HB159)	BE0104	BE0085
MHC Class I (H-2Kk, H-2Dk)	mouse	<i>in vivo</i> administration, FC	15-3-1S (HB13)	BE0158	BE0085



InVivoMab vs. InVivoPlus		
	InVivoMab > 95%	InVivoPlus > 95%
purity level		
protein aggregates validated at ≤5%		✓
azide and carrier protein free	✓	✓
endotoxin concentration	< 2EU/mg	< 1EU/mg
validated by immunoblot, FC, or ELISA		✓
tested for murine pathogens		✓
available in bulk quantities	✓	✓

Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
MHC Class I (H-2Kk, H-2Dk)	mouse	Functional assays, FC	16-1-2N (HB14)	BE0228	BE0085
MHC Class I (HLA-A, HLA-B, HLA-C)	human	Functional assays	W6/32	BE0079	BE0085
MHC class II (HLA-DR)	human/monkey	<i>in vitro</i> blocking of MHC class II HLA-DR, HLA class II binding assay, <i>in vitro</i> MHC class II HLA-DR expressing cell negative selection, WB, FC	L243	BE0306	BE0085
MHC class II (I-A)	mouse	<i>in vivo</i> blockade of TCR stimulation, FC	Y-3P	BE0178	BE0085
MHC Class II (I-A/I-E)	mouse	<i>in vivo</i> MHC II blockade, Functional assays, FC	M5/114	BE0108	BE0090
MHC II (I-Ak, I-As, I-As, I-Ag7)	mouse	<i>in vitro</i> MHC class II I-A blocking, <i>in vitro</i> MHC class II I-A expressing cell negative selection	10-3.6.2	BE0068	BE0085
MHC Class II (I-Ek/RT1-D)	mouse/rat	<i>in vivo</i> blocking of antigen presentation, FC	14-4-4S (HB32)	BE0167	BE0085
MHC Class II (β chain)	mouse	WB	KL277	BE0140	N/A
NK1.1	mouse	<i>in vivo</i> NK cell depletion, FC	PK136	BP0036	BP0085
NKG2A/C/E	mouse	<i>in vivo</i> and <i>in vitro</i> NKG2A blockade, IHC-F, FC	20D5	BE0321	BE0089
NKG2AB6	mouse	FC	16A11	BE0339	BE0086
NKG2D	mouse	<i>in vivo</i> NKG2D blockade	HMG2D	BE0111	BE0091
Nonclassical MHC Class I molecule Qa-1b	mouse	WB, IF	4C2.4A7.5H11	BE0165	BE0083
Notch4	mouse	<i>in vivo</i> Notch4 blocking, <i>in vitro</i> Notch4 stimulation, FC	HMN4-14	BE0129	BE0091
OX40 (CD134)	mouse	<i>in vivo</i> and <i>in vitro</i> OX40 activation	OX-86	BP0031	BP0088
OX40L (CD134L)	mouse	<i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization	RM134L	BE0033-1	BE0090
PD-1 (CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization	J43	BP0033-2	BP0091
PD-1 (CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BP0146	BP0089
PD-1 (CD279)	human	<i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice	J116	BE0188	BE0083
PD-1 (CD279)	human	<i>in vivo</i> PD-1 blockade in humanized mice, FC	J110	BE0193	BE0083
PD-1 (CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB	29F.1A12	BP0273	BP0089
PD-L1 (B7-H1)	mouse	<i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC	10F.9G2	BP0101	BP0090
PD-L1 (B7-H1)	human	<i>in vitro</i> PD-L1 blockade, Functional assays, IHC-F, FC	29E.2A3	BE0285	BE0086
PD-L2 (B7-DC)	mouse	<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC-F, FC	TY25	BE0112	BE0089
PSGL-1 (CD162)	mouse	<i>in vivo</i> PSGL-1 blockade, IHC-F	4RA10	BE0186	BE0088
RANKL (CD254)	mouse	<i>in vivo</i> RANKL blockade	IK22/5	BE0191	BE0089
Siglec-H	mouse	<i>in vivo</i> administration, FC	440c	BE0202	BE0090
TCR Vγ1.1/Cr4	mouse	FC	2.11	BE0257	BE0091
TCR γ/δ	mouse	<i>in vivo</i> TCR γ/δ neutralization, <i>in vitro</i> γ/δ T cell stimulation, <i>in vitro</i> γ/δ T cell purification, Functional assays, IP, FC	UC7-13D5	BE0070	BE0091
TCRβ	mouse	<i>in vivo</i> T cell depletion	H57-597 (HB218)	BE0102	BE0091
Ter-119	mouse	<i>in vivo</i> administration, Functional assays, FC	TER-119	BE0183	BE0090
TGF-β	mouse/human/rat/monkey/hamster/canine/bovine	<i>in vivo</i> and <i>in vitro</i> TGF-β neutralization	1D11.16.8	BP0057	BP0083
Thy1 (CD90)	mouse	<i>in vitro</i> T cell depletion	M5/49.4.1	BE0076	BE0089
Thy1.1 (CD90.1)	mouse	<i>in vivo</i> T cell depletion	19E12	BE0214	BE0085
Thy1.2 (CD90.2)	mouse	<i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion	30H12	BP0066	BP0090
TIGIT	mouse	<i>in vivo</i> TIGIT stimulation, FC	1G9	BE0274	BE0083
TIM-1 (CD365)	mouse	<i>in vivo</i> TIM-1 neutralization	RMT1-10	BE0113	BE0089
TIM-1 (CD365)	mouse	<i>in vivo</i> TIM-1 activation, <i>in vitro</i> T cell stimulation/activation, Functional assays, ELISA, FC	3B3	BE0289	BE0089
TIM-1 (CD365)	mouse	<i>in vivo</i> and <i>in vitro</i> TIM-1 blockade	3D10	BE0314	BE0088
TIM-3 (CD366)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BP0115	BP0089
TIM-3 (CD366)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	B8.2C12	BE0275	BE0088
TIM-4	mouse	<i>in vivo</i> and <i>in vitro</i> TIM-4 blockade, IF	RMT4-53	BE0171	BE0090
TIM-4	mouse	<i>in vitro</i> TIM-4 blocking, IF, FC	RMT 4-54	BE0225	BE0089
TIM-4	mouse	FC	F31-5G3	BE0344	BE0088
TL1A (TNFSF15)	mouse	<i>in vivo</i> TL1A neutralization, FC	5G4.2	BE0323	BE0091
TNFR2 (CD120b)	mouse	<i>in vivo</i> and <i>in vitro</i> TNFR2 blockade	TR75-54.7	BE0247	BE0091
TNFα	mouse	<i>in vivo</i> and <i>in vitro</i> TNFα neutralization	XT3.11	BP0058	BP0088
TNFα	mouse/rat/rabbit	<i>in vivo</i> TNFα neutralization, FC	TN3-19.12	BE0244	BE0091
VISTA	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of VISTA signaling, FC	13F3	BP0310	BP0091
Vβ4 TCR	mouse	<i>in vivo</i> administration, FC	KT4	BE0166	BE0090
Vβ8 TCR	mouse	FC	F23.1	BE0182	BE0085
Vγ2 TCR	mouse	<i>in vivo</i> γδ T cell depletion, FC	UC3-10A6	BE0168	BE0091



For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 15,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

**Bio X Cell**

[bioxcell.com](http://bioxcell.com) | 1.866.787.3444

[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.*  
Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell. © 2022 Bio X Cell

